The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 is a phase 3 interventional trial sponsored by Johns Hopkins University. As of 21 Nov 2026, it is recruiting participants. It studies Secretin in Gene Mutation, Germline Mutation Carrier and 3 more conditions. The registry lists an enrollment of 9,000 participants at 9 sites in 1 country. The registry lists a start date of 6 Jan 2014 and a primary completion date of 31 Dec 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02000089 |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Johns Hopkins University |
| Enrollment | 9,000 |
| Registered sites | 9 |
| Countries | 1 |
| Conditions | Gene Mutation, Germline Mutation Carrier, Lynch Syndrome, Pancreas Cancer and Peutz-Jeghers Syndrome (PJS) |
| Drugs | Secretin |
| Start | 6 Jan 2014 |
| Primary completion | 31 Dec 2028 |
| Study completion | 30 Jun 2029 |
| Last update posted | 22 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Michael Goggins, MD
Johns Hopkins University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven
James Farrell, MDRecruiting
- Johns Hopkins Hospital
Baltimore
Marcia I Canto, MDMichael Goggins, MDRecruiting
- Dana Farber Cancer Center, Harvard University
Boston
Matthew Yurgelun, MDSapna Syngal, MDRecruiting
- University of Michigan
Ann Arbor
Elena Stoffel, MDRecruiting
- Columbia University Medical Center
New York
Fay Kastrinos, MDRecruiting - Nyu Langone Medical Center
New York
Tamas Gonda, MDRecruiting
- Case Comprehensive Cancer Center, Case Western Medical Reserve
Cleveland
Amitabh Chak, MDRecruiting
- University of Pennsylvania
Philadelphia
Bryson Katona, MDRecruiting - University of Pittsburgh
Pittsburgh
Randall Brand, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02000089
Each answer restates registry values shown on this page.
What is NCT02000089?
NCT02000089 is a phase 3 interventional trial sponsored by Johns Hopkins University. It studies Secretin in Gene Mutation, Germline Mutation Carrier and 3 more conditions.
Is NCT02000089 recruiting?
As of 21 Nov 2026, it is recruiting participants. 9 of its 9 sites list their own status as recruiting.
Who leads NCT02000089?
The registry names Michael Goggins, MD (principal investigator, Johns Hopkins University) as the overall official.
Where does NCT02000089 run?
The registry lists 9 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02000089 study?
The registered drug and biological interventions are Secretin.
When is NCT02000089 expected to complete?
The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 30 Jun 2029. The sponsor last updated the record on 22 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.